Ann: Orthocell Appoints Exclusive Distributor in Australia, page-22

Mate that was probably a new tax year sell down. You've waited what, 4 years for this ATI trial and you are going to sell down now?

Its a sorry reflection of the poor quality of Australian media that 80% restoration of upper limb function in Paraplegics did not make the headlines. That a company has EMA; FDA and TGA approval in one aspect of many applications of its collagen scaffold has not caught the mainstream finance headlines is ridiculous. Australian bio-tech coverage by analysts in Oz is nearly non-existent. Media coverage even less professional. Its why an FDA/EMA/TGA approved company trades $100million market cap and you can be one of the biggest stock holders!!

IF (admittedly an IF), this thing makes a US partnership with J&J it will explode. I can only point to Fate (sorry, as usual), a $7 billion USD, phase 1/2 stem-cell company in part as a result of its JNJ partnership! If US investors wake up to an already FDA approved minnow like this in partnership with JNJ they are going to take one look at OCC vs FATE and marvel at the ridiculous valuation.